KR20240142481A - 엑토뉴클레오티드 피로포스파타제-포스포디에스테라제 1 (enpp1) 억제제 및 그의 용도 - Google Patents
엑토뉴클레오티드 피로포스파타제-포스포디에스테라제 1 (enpp1) 억제제 및 그의 용도 Download PDFInfo
- Publication number
- KR20240142481A KR20240142481A KR1020247028329A KR20247028329A KR20240142481A KR 20240142481 A KR20240142481 A KR 20240142481A KR 1020247028329 A KR1020247028329 A KR 1020247028329A KR 20247028329 A KR20247028329 A KR 20247028329A KR 20240142481 A KR20240142481 A KR 20240142481A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- compound
- pharmaceutically acceptable
- acceptable salt
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022074739 | 2022-01-28 | ||
| CNPCT/CN2022/074739 | 2022-01-28 | ||
| CN2022140318 | 2022-12-20 | ||
| CNPCT/CN2022/140318 | 2022-12-20 | ||
| PCT/CN2023/073579 WO2023143520A1 (en) | 2022-01-28 | 2023-01-28 | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240142481A true KR20240142481A (ko) | 2024-09-30 |
Family
ID=87470622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247028329A Pending KR20240142481A (ko) | 2022-01-28 | 2023-01-28 | 엑토뉴클레오티드 피로포스파타제-포스포디에스테라제 1 (enpp1) 억제제 및 그의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250101019A1 (https=) |
| EP (1) | EP4469456A4 (https=) |
| JP (1) | JP2025502943A (https=) |
| KR (1) | KR20240142481A (https=) |
| CN (1) | CN118871439A (https=) |
| AR (1) | AR128383A1 (https=) |
| AU (1) | AU2023213905A1 (https=) |
| CA (1) | CA3247162A1 (https=) |
| IL (1) | IL313821A (https=) |
| MX (1) | MX2024009216A (https=) |
| TW (1) | TW202340190A (https=) |
| WO (1) | WO2023143520A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024074128A1 (en) * | 2022-10-08 | 2024-04-11 | Insilico Medicine Ip Limited | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
| CN121793967A (zh) * | 2023-07-06 | 2026-04-03 | 英矽智能科技知识产权有限公司 | 外切核苷酸焦磷酸酶/磷酸二酯酶1 (enpp1)抑制剂组合及其用途 |
| WO2025026383A1 (en) * | 2023-08-02 | 2025-02-06 | Insilico Medicine Ip Limited | Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
| WO2025026377A1 (en) * | 2023-08-02 | 2025-02-06 | Insilico Medicine Ip Limited | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE912874A1 (en) * | 1990-08-15 | 1992-02-26 | British Bio Technology | Compounds |
| GB9200209D0 (en) * | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
| US6489338B2 (en) * | 2000-06-13 | 2002-12-03 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrimidine antiviral agents |
| KR101142363B1 (ko) * | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| EP2099796B1 (en) * | 2006-11-30 | 2011-06-01 | Genentech, Inc. | Aza-indolyl compounds and methods of use |
| WO2015038417A1 (en) * | 2013-09-10 | 2015-03-19 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
| CN111615388B (zh) * | 2017-07-27 | 2023-11-14 | 斯汀格瑞治疗股份有限公司 | 癌症免疫治疗剂 |
| CN111732584B (zh) * | 2019-03-25 | 2024-02-27 | 复旦大学 | 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途 |
| JP7598875B2 (ja) * | 2019-04-12 | 2024-12-12 | リボサイエンス リミティド ライアビリティ カンパニー | エクトヌクレオチドピロホスファターゼホスホジエステラーゼ１阻害剤としての二環式ヘテロアリール誘導体 |
| CN115151253B (zh) * | 2019-09-23 | 2025-04-15 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
| CA3291973A1 (en) * | 2021-01-29 | 2026-03-02 | Txinno Bioscience Inc. | Benzotriazole Derivative Having Inhibitory Activity Against Ectonucleotide Pyrophosphatase-Phosphodiesterase, and Use Thereof |
-
2023
- 2023-01-28 CN CN202380026751.8A patent/CN118871439A/zh active Pending
- 2023-01-28 JP JP2024539810A patent/JP2025502943A/ja active Pending
- 2023-01-28 WO PCT/CN2023/073579 patent/WO2023143520A1/en not_active Ceased
- 2023-01-28 US US18/832,564 patent/US20250101019A1/en active Pending
- 2023-01-28 IL IL313821A patent/IL313821A/en unknown
- 2023-01-28 EP EP23746397.1A patent/EP4469456A4/en active Pending
- 2023-01-28 MX MX2024009216A patent/MX2024009216A/es unknown
- 2023-01-28 KR KR1020247028329A patent/KR20240142481A/ko active Pending
- 2023-01-28 AU AU2023213905A patent/AU2023213905A1/en active Pending
- 2023-01-28 CA CA3247162A patent/CA3247162A1/en active Pending
- 2023-01-30 TW TW112102960A patent/TW202340190A/zh unknown
- 2023-01-30 AR ARP230100212A patent/AR128383A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL313821A (en) | 2024-08-01 |
| US20250101019A1 (en) | 2025-03-27 |
| EP4469456A4 (en) | 2025-12-31 |
| CN118871439A (zh) | 2024-10-29 |
| AU2023213905A1 (en) | 2024-07-11 |
| CA3247162A1 (en) | 2023-08-03 |
| MX2024009216A (es) | 2024-08-06 |
| WO2023143520A1 (en) | 2023-08-03 |
| AR128383A1 (es) | 2024-04-24 |
| EP4469456A1 (en) | 2024-12-04 |
| TW202340190A (zh) | 2023-10-16 |
| JP2025502943A (ja) | 2025-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11884680B2 (en) | Bromodomain inhibitors | |
| KR20240142481A (ko) | 엑토뉴클레오티드 피로포스파타제-포스포디에스테라제 1 (enpp1) 억제제 및 그의 용도 | |
| US11999713B2 (en) | Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof | |
| US10202360B2 (en) | Therapeutic compounds | |
| JP2024543512A (ja) | リジンアセチルトランスフェラーゼ６ａ（ｋａｔ６ａ）阻害剤およびその使用 | |
| US20130281438A1 (en) | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | |
| WO2024074128A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof | |
| US20250145624A1 (en) | Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof | |
| WO2023165528A1 (en) | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof | |
| CN114981256B (zh) | 干扰素基因刺激物sting的单环激动剂 | |
| CN110156782B (zh) | 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物 | |
| TWI860022B (zh) | 嘧啶化合物 | |
| WO2025026377A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof | |
| EA052691B1 (ru) | Ингибиторы эктонуклеотидпирофосфатазы-фосфодиэстеразы 1 (enpp1) и их применение | |
| HK40116343A (zh) | 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途 | |
| CN111808080B (zh) | 取代的吡啶或嘧啶化合物、其制备方法及其在医药上的应用 | |
| WO2023250439A1 (en) | Trex1 inhibitors and uses thereof | |
| AU2010242394B2 (en) | Purine derivative and antitumor agent using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |